Respiratory Syncytial Virus research hub
5 indexed studies · 1 currently recruiting
- recruitingPHASE2
Phase 2b Study of a Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Protein Vaccine Candidate in Adults 60 Years of Age and Older
This study is testing a new vaccine for adults aged 60 and over. It aims to protect against two common chest infections, RSV and HMPV. Researchers want to see how well it works and if it's safe. Half of the volunteers will get the vaccine, and half will get a dummy injection (placebo).
Australia · United Kingdom - active not recruitingPHASE1
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
This study is testing new mRNA vaccines against common winter viruses, RSV and hMPV, in babies and toddlers aged 5 to 24 months. Researchers want to see if the vaccines are safe and good at triggering the body's immune response.
United States · Panama · United Kingdom - active not recruitingPHASE2
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers
This study is looking at a new vaccine (mRNA-1345) for Respiratory Syncytial Virus (RSV) in pregnant women. It checks if the vaccine is safe and works well for mums-to-be, and also for their babies after they are born.
United States · Canada · Chile - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Pregnant Women, and Safety, and Immunogenicity in Infants Born to Vaccinated Mothers.
This study is testing a new vaccine for pregnant women to protect their babies from RSV, a common chest infection. We're looking at how safe the vaccine is, its side effects, and how well it helps the mother and baby fight off RSV.
Denmark - active not recruitingPHASE3
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults
This study is testing a new vaccine (mRNA-1345) to protect against Respiratory Syncytial Virus (RSV) in adults at higher risk. It aims to see how safe the vaccine is and how well the body's immune system responds to it. The study involves two groups: high-risk adults and organ transplant recipients.
United States · Canada · Puerto Rico